Interleukin-2 inhalation therapy in renal cell cancer: A case report and review of the literature

被引：0

作者：

Del Monte, Girolamo ^{[1
]}

Ferroni, Patrizia ^{[2
]}

Mariotti, Sabrina ^{[1
]}

Fossile, Emanuela ^{[1
]}

Guadagni, Fiorella ^{[2
]}

Roselli, Mario ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Dept Internal Med, Tor Vergata Clin Ctr, I-00133 Rome, Italy

[2] IRCCS San Raffaele Pisana, Dept Lab Med & Adv Biotechnol, Rome, Italy

来源：

IN VIVO | 2008年 / 22卷 / 04期

关键词：

renal cell cancer; interleukin-2; chemotherapy; metastatic disease;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Renal cell carcinoma (RCC) is the most common malignancy of the kidney. One third of RCC presents metastatic disease at the time of diagnosis, usually leading to a fatal outcome. Small response rates were seen with most cytotoxic agents including gemcitabine and vinorelbine, whereas systemic therapy with high doses of interleukin 2 (IL-2) has been shown to provide durable complete remissions. However, in consideration of its severe toxicity, IL-2 immunotherapy is restricted to selected patients. Aerosol IL-2 has been introduced as an alternative therapy in cancer patients. However, only very few data are available on its use in patients with pulmonary metastatic RCC. This paper briefly summarizes current clinical experience with the use of inhaled IL-2 therapy, either as a single therapy or in combination with other treatments. In addition, we report on a male patient with pulmonary metastasized RCC who achieved a durable complete response to combined gemcitabine/vinorelbine and interleukin-2 inhalation therapy.

引用

页码：481 / 488

页数：8

共 39 条

[1] Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens [J].

Amato, RJ .

ANNALS OF ONCOLOGY, 2005, 16 (01) :7-15

[2]

Amato RJ, 2000, SEMIN ONCOL, V27, P177

[3] Update on the role of interleukin 2 and other cytokines in the treatment of patients with Stage IV renal carcinoma [J].

Atkins, MB ;

Regan, M ;

McDermott, D .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6342S-6346S

[4]

ATKINS MB, 2003, CANC INVEST, V21, pS87

[5] Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma:: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J. ;

Kirchner, H. ;

Rebmann, U. ;

Soder, M. ;

Gertenbach, U. ;

Siebels, M. ;

Roigas, J. ;

Raschke, R. ;

Salm, S. ;

Schwindl, B. ;

Mueller, S. C. ;

Hauser, S. ;

Leiber, C. ;

Huland, E. ;

Heinzer, H. ;

Siemer, S. ;

Metzner, B. ;

Heynemann, H. ;

Fornara, P. ;

Reitz, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (04) :463-469

[6]

Bukowski R M, 2001, Semin Urol Oncol, V19, P148

[7]

Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO

[8]

2-H

[9] Current treatment of renal cell carcinoma [J].

De Mulder, PHM ;

van Herpen, CML ;

Mulders, PAF .

ANNALS OF ONCOLOGY, 2004, 15 :319-328

[10]

ELSON PJ, 1988, CANCER RES, V48, P7310

← 1 2 3 4 →